Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies

Oncology Letters
Bing XiaYizhuo Zhang

Abstract

It is becoming increasingly evident that B-cell receptor (BCR) signaling is central to the development and function of B cells. BCR signaling has emerged as a pivotal pathway and a key driver of numerous B-cell lymphomas. Disruption of BCR signaling can be lethal to malignant B cells. Recently, kinase inhibitors that target BCR signaling have induced notable clinical responses. These inhibitors include spleen tyrosine kinase, mammalian target of rapamycin, phosphoinositide 3'-kinase and Bruton's tyrosine kinase (BTK). Ibrutinib, an oral irreversible BTK inhibitor, has emerged as a promising targeted therapy for patients with B-cell malignancies. The present review discusses the current understanding of BTK-mediated BCR signaling in the biology and pathobiology of normal and malignant B cells, and the cellular interaction with the tumor microenvironment. The data on ibrutinib in the preclinical and clinical settings is also discussed, and perspectives for the future use of ibrutinib are outlined.

References

Dec 1, 1994·European Journal of Immunology·H C GenevierC Kinnon
Dec 4, 2002·Nature Reviews. Immunology·Hiroaki Niiro, Edward A Clark
Jun 15, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jonathan M IrishRonald Levy
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Dec 15, 2010·Nature Reviews. Clinical Oncology·Anas Younes
Aug 6, 2011·Blood·Freda K StevensonGraham Packham
Aug 17, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan W Friedberg
Jun 13, 2012·Current Hematologic Malignancy Reports·Vaishalee P Kenkre, Brad S Kahl
Aug 16, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John M TimmermanJohn M Pagel
Sep 26, 2012·The Cancer Journal·Michael Y Choi, Thomas J Kipps
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Oct 23, 2012·International Journal of Hematology·Mark RoschewskiWyndham H Wilson
Mar 2, 2013·Nature Reviews. Drug Discovery·Ryan M Young, Louis M Staudt
Apr 27, 2013·British Journal of Haematology·Alan D Ramsay, Manuel Rodriguez-Justo
May 16, 2013·Scandinavian Journal of Immunology·L VargasC I E Smith
May 30, 2013·American Society of Clinical Oncology Educational Book·Nathan Fowler, Yasuhiro Oki
Jun 15, 2013·Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti·M MrázJ Mayer
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jul 26, 2013·Nature Reviews. Immunology·Robert C Rickert

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.